Phase 2 results, multi-omics gut microbiome data, and Phase 3 readiness milestones announced via Business Wire.
Read More
Primary endpoint met with high rates of clinical cure at day 12 Very low rates of recurrence...
Read More
Announcement Regarding CRS0540: Crestone, Inc. and Praedicare Inc. Announce the Publication of...
Read More
June 8, 2021 – Announcement: Crestone, Inc. joins the Antimicrobials Working Group to Combat...
Read More
June 7, 2021 – Announcement: Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial...
Read More
July 1, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Development Through...
Read More
May 29, 2020 – Announcement: Crestone, Inc. receives $250,000 Grant from State of Colorado...
Read More
Apr 27, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Preclinical Development...
Read More
CFF Funding Secured Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of...
Read More
Crestone had the opportunity to showcase its innovative research at the 9th AMR Conference in Basel, Switzerland, and ICDS 2024 in Bled, Slovenia.
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor or a team member.
Have a question or comment? Follow the link below to contact us about general inquiries.
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
If you're interested in becoming an investor to help fund our research and development, contact us today.
